logo

For the Inventor, By the Inventor

Siegenfeld, Austria

Robert Schlegl

This inventor holds 28 USPTO granted patents and 13 published patent applications and 17 EPO patents, primarily in Vaccine Development. Top assignees: Valneva Austria Gmbh, Valneva Se, Biopharma Credit Plc, as Collateral Agent. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Schlegl. Retrieved from https://idiyas.com/inventor/robert-schlegl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 28 

% Patents Active = 85.7

 

Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 82(Granted Patents)


Location History:

  • Siegnenfeld, AT (2014)
  • Siegenfeld, AT (2016 - 2024)

Company Filing History:

goldMedal18 out of 46 
 
Valneva Austria Gmbh
 patents
silverMedal8 out of 15 
 
Valneva Se
 patents
bronzeMedal2 out of 5 
 
Biopharma Credit Plc, as Collateral Agent
 patents
4. 1 out of 66 
 
Dynavax Technologies Corporation
 patents
where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Zika Virus Vaccine
Virus Purification
Aluminum Compounds
SARS-CoV-2
Immunogenic Compositions
Chikungunya Virus
CpG-Adjuvanted
Aseptic Purification
OspA Fragments
IC31 Nanoparticles
Therapeutics
Vaccines
28 patents (USPTO):Explore Patents
1. 12605436 - CHIKUNGUNYA VACCINE FORMULATIONS (2026-04-21),
2. 12564625 - METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3 (2026-03-03),
3. 12527863 - METHODS FOR PREPARING ALUMINUM PRECIPITATE COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES (2026-01-20),
4. 12214033 - Virus purification (2025-02-04),
5. 12102673 - Zika virus vaccine (2024-10-01),
6. 12011477 - Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3 (2024-06-18),
7. 12005111 - Zika virus vaccine (2024-06-11),
8. 11951163 - Zika virus vaccine (2024-04-09),
9. 11684669 - CpG-adjuvanted SARS-CoV-2 virus vaccine (2023-06-27),
10. 11629339 - Aseptic purification process for viruses (2023-04-18),
11. 11484587 - Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3 (2022-11-01),
12. 11466058 - Mutant fragments of OspA and methods and uses relating thereto (2022-10-11),
13. 11331382 - Zika virus purification (2022-05-17),
14. 11219681 - Zika virus vaccine (2022-01-11),
15. 11110170 - Aluminum compounds for use in therapeutics and vaccines (2021-09-07),

Title: Robert Schlegl: Innovator in Virus Research and Vaccine Development

Introduction: Robert Schlegl, based in Siegenfeld, Austria, is a prominent inventor with an impressive portfolio of 25 patents. His work, primarily focused on viral purification processes and vaccine development, has significantly contributed to the field of infectious disease research and prevention.

Latest Patents: Among Schlegl's latest inventions are groundbreaking patents on virus purification. These patents detail novel processes for purifying infectious virus particles, highlighting the crucial role of protamine in these methods. Additionally, he has developed patents related to Zika virus vaccines, outlining innovative compositions and methods for producing and administering these vaccines to individuals in need.

Career Highlights: Throughout his career, Schlegl has worked with notable companies such as Valneva Austria GmbH and Valneva SE. His contributions in these organizations have played a pivotal role in advancing research and development in the biopharmaceutical sector, particularly in vaccine technology.

Collaborations: Schlegl has collaborated with esteemed colleagues, including Michael Weber and Jürgen Heindl-Wruss. These partnerships have facilitated shared knowledge and expertise, further enhancing the innovative projects Schlegl is involved in.

Conclusion: Robert Schlegl stands out as a key figure in the field of viral research and vaccine development. His extensive patent portfolio and collaborative efforts underscore his commitment to advancing medical science and improving public health through innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…